A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Oral Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY3202328
Phase of Trial: Phase I
Latest Information Update: 16 Mar 2017
At a glance
- Drugs LY 3202328 (Primary) ; Atorvastatin; Simvastatin
- Indications Dyslipidaemias
- Focus Adverse reactions
- Sponsors Eli Lilly
- 10 Mar 2017 Status changed from active, no longer recruiting to completed.
- 05 Jan 2017 Planned End Date changed from 1 Jun 2017 to 1 Feb 2017.
- 05 Jan 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Feb 2017.